Vivus Obesity Pill Scores With Phase III Data, But Still Faces Major Market Hurdles
Qnexa combines two generics, but Vivus Chief Operating Officer Peter Tam says: "We are not concerned about generic substitution."
Qnexa combines two generics, but Vivus Chief Operating Officer Peter Tam says: "We are not concerned about generic substitution."